EXTENDED AML PANEL (BCR/ABL,AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) (SDL11156)

This panel tests multiple AML mutations for diagnosis and prognosis. Results guide chemotherapy or targeted therapies, stratifying risk in acute myeloid leukemia patients.